secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001104659-26-022572
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma Phase 3 CYPRESS study fails; plans 50% workforce cut and strategic review
--------------------------------------------------------------------------------

- Phase 3 CYPRESS study of ampreloxetine for nOH in MSA did not meet primary endpoint (OHSA composite); program halted.
- Organizational restructuring to reduce cost base ~60% (~$70M) and impact ~50% of workforce; R&D wound down, G&A cut ~50%.
- Board's Strategic Review Committee accelerating evaluation of alternatives including a sale of the company.
- Preliminary cash $326.5M at Q4 2025; expected ~$400M at Q1 2026 after $25M YUPELRI and $50M TRELEGY milestones received.
- YUPELRI FY2025 net sales $266.6M (+12% YoY); company expects ~$60-70M annualized cash flow from restructuring and YUPELRI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926022572/0001104659-26-022572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926022572/tm267846d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-022572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer